- Juva Life (JUVA) announced their newly revised WCG IRB-approved cannabis patient registry, the JuLi Registry
- The Registry, listed on clinicaltrials.gov, aims at amassing one of the world’s largest data sets of real-world clinical evidence on the potential health benefits of cannabis
- Once completed, Juva will have one of the largest data sets of its kind
- Juva Life employs state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products
- Juva Life Inc. (JUVA) remains unchanged, trading at C$0.175 per share at 1:08 pm ET
Juva Life (JUVA) announced their newly revised WCG IRB-approved cannabis patient registry, the JuLi Registry.
The JuLi Registry is a WCG IRB -approved multi-year study conducted through Juva Life’s cannabis research division. The Registry, listed on clinicaltrials.gov, aims at amassing one of the world’s largest data sets of real-world clinical evidence on the potential health benefits of cannabis.
The Registry enjoys participation from best-in-class cannabis and cannabidiol (CBD) brands. It includes products from CannaCraft, dosist, LEVEL, San Benito Hemp Company, Sunderstorm, and WYLD.
Once completed, Juva will have one of the most extensive data sets of its kind. It will be able to leverage the findings in both its nutraceutical wellness, drug development and clinical programs. This real-world observational data, overseen by physicians and other clinicians, will be presented to various regulatory bodies to show the potential therapeutic benefits of cannabis and hemp-derived compounds.
The registry aims to collect data on cannabis formulations, chemical composition, dosing and utilization, and the effectiveness of cannabis products in addressing designated medical concerns.
Juva Life employs state-of-the-art pharmaceutical research and development to discover, develop and commercialize safe and effective cannabis products.
Juva Life Inc. (JUVA) remains unchanged, trading at C$0.175 per share at 1:08 pm ET.